Kiora Pharmaceuticals, Inc. News Releases

Kiora Pharmaceuticals Appoints Keith J. Lane as Executive Vice President of Global Clinical Development and Regulatory Affairs

Tue, 08 Sep 2026 07:00:00 -0400

Clinical development executive brings over 20 years of ophthalmology experience supporting U.S. and global clinical trials to support the advancement of Kiora's pipeline and new asset opportunities Encinitas, California--(Newsfile Corp. - September 8, 2026) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") today announced the appointment of Keith J. Lane, MBA, as Executive Vice President of Clinical Development and Regulatory Affairs. Mr. Lane has over 20 years of...

Kiora Pharmaceuticals Licenses South Korean Ophthalmic Development and Commercialization Rights for KIO-301 to Chong Kun Dang Pharmaceutical Corporation

Wed, 19 Aug 2026 07:00:00 -0400

Encinitas, California--(Newsfile Corp. - August 19, 2026) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora") today announced that it has licensed the development and commercialization rights for KIO-301 in South Korea for ophthalmic indications to Chong Kun Dang Pharmaceutical Corporation (CKD). CKD, based in Seoul, is one of South Korea's leading pharmaceutical companies. Under the agreement, Kiora will receive a $1 million upfront payment and is eligible to receive development and...

Kiora Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Fri, 07 Aug 2026 07:00:00 -0400

Encinitas, Califfornia--(Newsfile Corp. - August 7, 2026) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) today reported financial results for the second quarter ended June 30, 2026, and provided an update on its clinical pipeline of small-molecule therapies for retinal diseases and its corporate development activities.Second Quarter 2026 and Recent HighlightsAdvanced enrollment in the Phase 2 ABACUS-2 clinical trial of KIO-301 into the higher-dose cohortContinued enrollment in the higher-dose...

Kiora Pharmaceuticals to Participate in Piper Sandler Virtual Ophthalmology Symposium

Thu, 02 Jul 2026 07:00:00 -0400

Encinitas, California--(Newsfile Corp. - July 2, 2026) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) today announced that it will participate in an investor fireside chat at the Piper Sandler Virtual Ophthalmology Symposium.Presentation DetailsDate: Thursday, July 9, 2026Time: 2:30 p.m. Eastern Daylight TimeLive Presentation: Available on Kiora's Investor Relations homepage at ir.kiorapharma.comReplay: Available for 90 days on Kiora's Investor Relations Events page at...

Kiora Pharmaceuticals Reports its Ion Channel Modulator, KIO-300, Suppressed Seizure Activity in Preclinical Epilepsy Model

Thu, 18 Jun 2026 07:00:00 -0400

Data Presented at Epilepsy Foundation Pipeline Conference Demonstrated Significant Reduction in Epileptiform Activity: KIO-300 is the active pharmaceutical ingredient of KIO-301, Kiora's ongoing Phase 2 clinical program in vision restoration in patients with gene mutation-agnostic Retinitis Pigmentosa Encinitas, California--(Newsfile Corp. - June 18, 2026) - Kiora Pharmaceuticals (NASDAQ: KPRX) today announced preclinical data showing that KIO-300, part of the company's novel ion channel...

Kiora Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update

Fri, 08 May 2026 07:00:00 -0400

Encinitas, California--(Newsfile Corp. - May 8, 2026) - Kiora Pharmaceuticals (NASDAQ: KPRX) today reported financial results for the first quarter ended March 31, 2026, and provided an update on its clinical pipeline of small molecules for the treatment of retinal diseases.First Quarter 2026 and Recent HighlightsEnrollment in the Phase 2 ABACUS-2 study of KIO-301 remains very active, with expansion of clinical trial sites to accommodate the strong patient demand to participate in the trial...

Kiora's Phase 1 ABACUS Study of KIO-301 in Retinitis Pigmentosa Published in Nature Medicine; Phase 2 Trial Underway

Tue, 14 Apr 2026 07:00:00 -0400

Encinitas, California--(Newsfile Corp. - April 14, 2026) - Kiora Pharmaceuticals (NASDAQ: KPRX) today announced the publication of the results from its Phase 1 ABACUS-1 study of KIO-301 in Nature Medicine. The publication adds clinical detail to a program aimed at restoring light responsiveness with a small molecule "photoswitch" in patients with the advanced inherited retinal disease, retinitis pigmentosa. The publication may be accessed at the following link...

Kiora Pharmaceuticals Announces Private Placement for Up to $24 Million Led by Perceptive Advisors

Tue, 07 Apr 2026 07:00:00 -0400

Sole investors are Perceptive Advisors (new) and ADAR1 Capital Management Encinitas, California--(Newsfile Corp. - April 7, 2026) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) (the "Company"), today announced that it has closed on a private placement providing up to $24 million in gross proceeds, consisting of $5.0 million in upfront funding and up to an additional $19 million upon the exercise of accompanying milestone-based warrants. The sole investors in the private placement are Perceptive...

Kiora Pharmaceuticals Announces Management Team Changes

Thu, 02 Apr 2026 16:30:00 -0400

Encinitas, California--(Newsfile Corp. - April 2, 2026) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") today announced that Eric J. Daniels, M.D., MBA, will depart from his role as Chief Development Officer on April 17, 2026, to pursue other opportunities. The Company has initiated a search for his successor. "Eric has made many important contributions to Kiora during his time with the Company," said Brian M. Strem, Ph.D., President and Chief Executive Officer of Kiora....

Kiora Pharmaceuticals Reports Fourth-Quarter and Full-Year 2025 Results; Company Advances Retinal Disease Pipeline with Two Active Phase 2 Clinical Trials

Wed, 25 Mar 2026 07:00:00 -0400

Encinitas, California--(Newsfile Corp. - March 25, 2026) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") today announced financial results for the fourth quarter and full year ended December 31, 2025, and provided a year-end business update on its pipeline of small molecules for the treatment of retinal diseases.Key fourth-quarter, full-year 2025, and recent corporate highlights include:Advanced KIO-301 from regulatory clearance to patient dosing in ABACUS-2, a Phase 2...